keep Reason 5 O O
stranglehold Reason 5 O O
on Reason 5 O O
COVID Reason 5 O O
vaccines, Reason 5 O O
though Reason 5 O O
you Reason 5 O O
paid Reason 5 O O
for Reason 5 O O
the Reason 5 O O
research Reason 5 O O
The Reason 5 O O
biotech Reason 5 O O
company Reason 5 O O
Moderna Reason 5 O O
injected Reason 5 O O
a Reason 5 O O
new Reason 5 O O
dose Reason 5 O O
of Reason 5 O O
optimism Reason 5 O O
into Reason 5 O O
the Reason 5 O O
fight Reason 5 O O
against Reason 5 O O
COVID-19 Reason 5 O O
on Reason 5 O O
Monday Reason 5 O O
by Reason 5 O O
announcing Reason 5 O O
that Reason 5 O O
its Reason 5 O O
vaccine Reason 5 O O
candidate Reason 5 O O
had Reason 5 O O
shown Reason 5 O O
[a Reason 5 O O
success Reason 5 O O
rate Reason 5 O O
of Reason 5 O O
94.5% Reason 5 O O
in Reason 5 O O
clinical Reason 5 O O
trials](https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy). Reason 5 O O
The O O O O
announcement, O O O O
however, O O O O
raises O O O O
new O O O O
questions O O O O
about O O O O
how O O O O
a O O O O
successful O O O O
vaccine O O O O
will O O O O
be O O O O
distributed O O O O
to O O O O
the O O O O
public O O O O
— O O O O
how O O O O
fast, O O O O
how O O O O
broadly O O O O
and O O O O
at O O O O
what O O O O
price? O O O O
That's O O O O
especially O O O O
relevant O O O O
for O O O O
the O O O O
Moderna O O O O
vaccine O O O O
because O O O O
federal O O O O
funding O O O O
of O O O O
the O O O O
company's O O O O
effort O O O O
approaches O O O O
$1 O O O O
billion, O O O O
and O O O O
because O O O O
the O O O O
government O O O O
owns O O O O
at O O O O
least O O O O
one O O O O
patent O O O O
crucial O O O O
for O O O O
the O O O O
product's O O O O
manufacture. O O O O
Moderna Reason 2 O O
retains Reason 2 O O
worldwide Reason 2 O O
rights Reason 2 O O
to Reason 2 O O
develop Reason 2 O O
and Reason 2 O O
commercialize Reason 2 O O
mRNA-1273...Moderna Reason 2 O O
will Reason 2 O O
realize Reason 2 O O
all Reason 2 O O
the Reason 2 O O
profits Reason 2 O O
from Reason 2 O O
our Reason 2 O O
COVID-19 Reason 2 O O
vaccine. Reason 2 O O
— Reason 2 O O
Stephane Reason 2 O O
Bancel, Reason 2 O O
Moderna Reason 2 O O
CEO Reason 2 O O
Despite O O O O
that, O O O O
Moderna O O O O
remains O O O O
in O O O O
control O O O O
of O O O O
manufacturing O O O O
rights O O O O
to O O O O
the O O O O
product, O O O O
formally O O O O
designated O O O O
mRNA-1273, O O O O
from O O O O
which O O O O
it's O O O O
expecting O O O O
to O O O O
record O O O O
blockbuster O O O O
profits. O O O O
"I Reason 1 O O
believe Reason 1 O O
that Reason 1 O O
if Reason 1 O O
we Reason 1 O O
launch Reason 1 O O
mRNA-1273, Reason 1 O O
we Reason 1 O O
will Reason 1 O O
exit Reason 1 O O
the Reason 1 O O
COVID Reason 1 O O
pandemic Reason 1 O O
crisis Reason 1 O O
in Reason 1 O O
a Reason 1 O O
unique Reason 1 O O
position," Reason 1 O O
Moderna Reason 1 O O
Chief Reason 1 O O
Executive Reason 1 O O
Stephane Reason 1 O O
Bancel Reason 1 O O
told Reason 1 O O
investors Reason 1 O O
after Reason 1 O O
the Reason 1 O O
release Reason 1 O O
of Reason 1 O O
the Reason 1 O O
company's Reason 1 O O
third-quarter Reason 1 O O
earnings Reason 1 O O
Oct. Reason 1 O O
29. Reason 1 O O
"Moderna Reason 1 O O
retains Reason 1 O O
worldwide Reason 1 O O
rights Reason 1 O O
to Reason 1 O O
develop Reason 1 O O
and Reason 1 O O
commercialize Reason 1 O O
mRNA-1273," Reason 1 O O
Bancel Reason 1 O O
said. Reason 1 O O
"Without Reason 1 O O
a Reason 1 O O
corporate Reason 1 O O
partner, Reason 1 O O
Moderna Reason 1 O O
will Reason 1 O O
realize Reason 1 O O
all Reason 1 O O
the Reason 1 O O
profits Reason 1 O O
from Reason 1 O O
our Reason 1 O O
COVID-19 Reason 1 O O
vaccine.... Reason 1 O O
We Reason 1 O O
should Reason 1 O O
have Reason 1 O O
a Reason 1 O O
unique Reason 1 O O
cash Reason 1 O O
position Reason 1 O O
at Reason 1 O O
the Reason 1 O O
end Reason 1 O O
of Reason 1 O O
2021." Reason 1 O O
The Reason 1 O O
company Reason 1 O O
estimates Reason 1 O O
the Reason 1 O O
potential Reason 1 O O
profits Reason 1 O O
in Reason 1 O O
the Reason 1 O O
billions Reason 1 O O
of Reason 1 O O
dollars. Reason 1 O O
Lots O O O O
more O O O O
needs O O O O
to O O O O
be O O O O
known O O O O
about O O O O
the O O O O
Pfizer O O O O
vaccine O O O O
before O O O O
COVID-19 O O O O
is O O O O
beaten. O O O O
That Reason 3 O O
suggests Reason 3 O O
that Reason 3 O O
Moderna Reason 3 O O
doesn't Reason 3 O O
expect Reason 3 O O
the Reason 3 O O
U.S. Reason 3 O O
government Reason 3 O O
to Reason 3 O O
exploit Reason 3 O O
its Reason 3 O O
own Reason 3 O O
rights Reason 3 O O
to Reason 3 O O
the Reason 3 O O
vaccine. Reason 3 O O
That's Reason 3 O O
an Reason 3 O O
old Reason 3 O O
story Reason 3 O O
in Reason 3 O O
the Reason 3 O O
pharmaceutical Reason 3 O O
industry, Reason 3 O O
which Reason 3 O O
has Reason 3 O O
profited Reason 3 O O
from Reason 3 O O
billions Reason 3 O O
of Reason 3 O O
dollars Reason 3 O O
in Reason 3 O O
government Reason 3 O O
scientific Reason 3 O O
research Reason 3 O O
without Reason 3 O O
returning Reason 3 O O
much, Reason 3 O O
if Reason 3 O O
anything, Reason 3 O O
to Reason 3 O O
the Reason 3 O O
taxpayers. Reason 3 O O
This Reason 3 O O
mismatch Reason 3 O O
is Reason 3 O O
likely Reason 3 O O
to Reason 3 O O
become Reason 3 O O
the Reason 3 O O
topic Reason 3 O O
of Reason 3 O O
more Reason 3 O O
bitterness Reason 3 O O
if Reason 3 O O
the Reason 3 O O
drug Reason 3 O O
industry Reason 3 O O
hampers Reason 3 O O
efforts Reason 3 O O
to Reason 3 O O
roll Reason 3 O O
out Reason 3 O O
COVID-19 Reason 3 O O
cures Reason 3 O O
globally. Reason 3 O O
The O O O O
potential O O O O
damage O O O O
to O O O O
the O O O O
fight O O O O
against O O O O
COVID-19 O O O O
may O O O O
already O O O O
be O O O O
visible O O O O
on O O O O
the O O O O
horizon. O O O O
"One Reason 1 O O
way Reason 1 O O
we Reason 1 O O
have Reason 1 O O
considerably Reason 1 O O
slowed Reason 1 O O
the Reason 1 O O
global Reason 1 O O
timetable," Reason 1 O O
says Reason 1 O O
Peter Reason 1 O O
Maybarduk, Reason 1 O O
director Reason 1 O O
of Reason 1 O O
the Reason 1 O O
Access Reason 1 O O
to Reason 1 O O
Medicines Reason 1 O O
program Reason 1 O O
at Reason 1 O O
the Reason 1 O O
advocacy Reason 1 O O
group Reason 1 O O
Public Reason 1 O O
Citizen, Reason 1 O O
"is Reason 1 O O
by Reason 1 O O
giving Reason 1 O O
grants Reason 1 O O
to Reason 1 O O
companies Reason 1 O O
and Reason 1 O O
asking Reason 1 O O
them Reason 1 O O
to Reason 1 O O
develop Reason 1 O O
manufacturing Reason 1 O O
arrangements Reason 1 O O
that Reason 1 O O
are Reason 1 O O
in Reason 1 O O
their Reason 1 O O
interest Reason 1 O O
rather Reason 1 O O
than Reason 1 O O
pooling Reason 1 O O
resources Reason 1 O O
and Reason 1 O O
saying Reason 1 O O
we're Reason 1 O O
going Reason 1 O O
to Reason 1 O O
teach Reason 1 O O
the Reason 1 O O
world Reason 1 O O
how Reason 1 O O
to Reason 1 O O
make Reason 1 O O
these Reason 1 O O
vaccines Reason 1 O O
and Reason 1 O O
using Reason 1 O O
all Reason 1 O O
the Reason 1 O O
available Reason 1 O O
manufacturing Reason 1 O O
capacity." Reason 1 O O
The O O O O
issue O O O O
is O O O O
relevant O O O O
to O O O O
more O O O O
than O O O O
merely O O O O
Moderna's O O O O
vaccine O O O O
candidate. O O O O
Pfizer, O O O O
which O O O O
has O O O O
also O O O O
developed O O O O
a O O O O
promising O O O O
vaccine O O O O
based O O O O
on O O O O
a O O O O
technology O O O O
similar O O O O
to O O O O
Moderna's, O O O O
has O O O O
said O O O O
it O O O O
declined O O O O
funding O O O O
from O O O O
a O O O O
key O O O O
government O O O O
vaccine O O O O
development O O O O
program. O O O O
But O O O O
the O O O O
company O O O O
has O O O O
received O O O O
[a O O O O
$1.95-billion O O O O
government O O O O
contract](https://www.latimes.com/business/story/2020-11-09/hiltzik-pfizer-coronavirus-covid19-vaccine-news-encouraging) O O O O
to O O O O
manufacture O O O O
100 O O O O
million O O O O
doses O O O O
of O O O O
its O O O O
product O O O O
if O O O O
it's O O O O
proved O O O O
effective. O O O O
The Reason 5 O O
Moderna Reason 5 O O
and Reason 5 O O
Pfizer Reason 5 O O
vaccines Reason 5 O O
use Reason 5 O O
messenger-RNA Reason 5 O O
to Reason 5 O O
instruct Reason 5 O O
human Reason 5 O O
cells Reason 5 O O
on Reason 5 O O
how Reason 5 O O
to Reason 5 O O
create Reason 5 O O
antibodies Reason 5 O O
for Reason 5 O O
the Reason 5 O O
virus Reason 5 O O
that Reason 5 O O
causes Reason 5 O O
COVID-19. Reason 5 O O
Both Reason 5 O O
Moderna Reason 5 O O
and Reason 5 O O
Pfizer, Reason 5 O O
along Reason 5 O O
with Reason 5 O O
other Reason 5 O O
drug Reason 5 O O
companies, Reason 5 O O
have Reason 5 O O
benefited Reason 5 O O
from Reason 5 O O
government Reason 5 O O
investments Reason 5 O O
in Reason 5 O O
basic Reason 5 O O
science Reason 5 O O
in Reason 5 O O
the Reason 5 O O
form Reason 5 O O
of Reason 5 O O
grants Reason 5 O O
to Reason 5 O O
university Reason 5 O O
and Reason 5 O O
other Reason 5 O O
academic Reason 5 O O
scientists. Reason 5 O O
Indeed, Reason 5 O O
funding Reason 5 O O
from Reason 5 O O
the Reason 5 O O
National Reason 5 O O
Institutes Reason 5 O O
of Reason 5 O O
Health Reason 5 O O
underwrote Reason 5 O O
"published Reason 5 O O
research Reason 5 O O
associated Reason 5 O O
with Reason 5 O O
every Reason 5 O O
one Reason 5 O O
of Reason 5 O O
the Reason 5 O O
210 Reason 5 O O
new Reason 5 O O
drugs Reason 5 O O
approved Reason 5 O O
by Reason 5 O O
the Reason 5 O O
Food Reason 5 O O
and Reason 5 O O
Drug Reason 5 O O
Administration Reason 5 O O
from Reason 5 O O
2010-2016," Reason 5 O O
according Reason 5 O O
to Reason 5 O O
[a Reason 5 O O
2018 Reason 5 O O
survey Reason 5 O O
by Reason 5 O O
scholars Reason 5 O O
at Reason 5 O O
Bentley Reason 5 O O
University](https://www.pnas.org/content/115/10/2329) Reason 5 O O
in Reason 5 O O
Waltham, Reason 5 O O
Mass. Reason 5 O O
The O O O O
survey O O O O
estimated O O O O
that O O O O
some O O O O
$100 O O O O
billion O O O O
in O O O O
government O O O O
grants O O O O
funded O O O O
basic O O O O
research O O O O
that O O O O
drug O O O O
companies O O O O
built O O O O
upon O O O O
to O O O O
develop O O O O
their O O O O
products O O O O
